UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (2) | 10/20/2025 | Common Stock | 20,000 | $ 6.94 | D | |
Stock Option (right to buy) | (2) | 03/30/2026 | Common Stock | 6,666 | $ 8.51 | D | |
Stock Option (right to buy) | (2) | 05/31/2026 | Common Stock | 6,666 | $ 11.66 | D | |
Stock Option (right to buy) | (2) | 09/14/2026 | Common Stock | 12,750 | $ 12.59 | D | |
Stock Option (right to buy) | (2) | 02/09/2027 | Common Stock | 38,200 | $ 10.9 | D | |
Stock Option (right to buy) | (3) | 02/15/2028 | Common Stock | 30,000 | $ 10.09 | D | |
Stock Option (right to buy) | (4) | 08/30/2028 | Common Stock | 7,200 | $ 12.29 | D | |
Stock Option (right to buy) | (5) | 02/11/2029 | Common Stock | 53,350 | $ 6.71 | D | |
Stock Option (right to buy) | (6) | 02/12/2030 | Common Stock | 84,000 | $ 7.54 | D | |
Stock Option (right to buy) | (7) | 06/10/2030 | Common Stock | 10,000 | $ 9.17 | D | |
Stock Option (right to buy) | (8) | 02/16/2031 | Common Stock | 94,000 | $ 11.41 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Stephens Kristin C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140 |
Chief Development Officer |
/s/ Kristin Stephens | 06/10/2021 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022. |
(2) | This option is fully vested. |
(3) | Option vested as to 25% of the shares on February 28, 2019 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2022. |
(4) | Option vested as to 25% of the shares on August 31, 2019 with the remaining shares vesting in equal monthly installments thereafter through August 31, 2022. |
(5) | Option vested as to 25% of the shares on February 29, 2020 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2023. |
(6) | Option vested as to 25% of the shares on February 28, 2021 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2024. |
(7) | Option vests as to 25% of the shares on June 11, 2021 with the remaining shares vesting in equal monthly installments thereafter through June 11, 2024. |
(8) | Option vests as to 25% of the shares on February 28, 2022 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2025. |
Remarks: Exhibit 24: Power of Attorney |